Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435262 | 0.69 | HPGDS (0.33) | LTA4HHPGDS | |
| SCHEMBL100765 | 0.68 | HPGDS (0.46) | LTA4HHPGDS | |
| SCHEMBL1190969 | 0.67 | HPGDS (0.33) | LTA4HHPGDS | |
| SCHEMBL611280 | 0.67 | HPGDS (0.41) | LTA4HHPGDS | |
| SCHEMBL7376054 | 0.65 | HPGDS (0.40) | LTA4HHPGDS | |
| SCHEMBL7183288 | 0.65 | HPGDS (0.36) | LTA4HHPGDS | |
| SCHEMBL5759138 | 0.65 | — | — | |
| SCHEMBL3953551 | 0.64 | HPGDS (0.38) | LTA4HHPGDS | |
| SCHEMBL912864 | 0.64 | LTA4H (0.37) | LTA4HHPGDS | |
| SCHEMBL21260075 | 0.63 | HPGDS (0.44) | LTA4HHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2021-06-24 | — | — | US | claimed |
| EP-3405465-A1 | IRAK4 INHIBITING AGENTS | Biogen MA Inc. (US) | 2018-11-28 | — | — | EP | claimed |
| WO-2017127430-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2017-07-27 | — | — | WO | claimed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | claimed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | claimed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | claimed |
| EP-3405465-B1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2021-06-24 | — | — | US | disclosed |
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3405465-A1 | IRAK4 INHIBITING AGENTS | Biogen MA Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127430-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2441757-A1 | Aurora kinase inhibitors from an encoded small molecule library | Praecis Pharmaceuticals Incorporated (US) | 2012-04-18 | — | — | EP | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | PIERSON EDWARD (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040087575-A1 | Therapeutic chromone compounds | SPORT COURT INTERNATIONAL, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087575-A1 | Therapeutic chromone compounds | HTR1B, HTR1A, HTR3B | LTA4H 3448/4885HPGDS 1532/4885 |
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | LTA4H 1948/4885HPGDS 3358/4885 |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | LTA4H 1541/4885HPGDS 3625/4885 |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | LTA4H 1959/4885HPGDS 460/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | LTA4H 1948/4885HPGDS 3358/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | LTA4H 2023/4885HPGDS 3245/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | LTA4H 2023/4885HPGDS 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.